Optimised electronic patient records to improve clinical monitoring of HIV-positive patients in rural South Africa (MONART trial): study protocol for a cluster-randomised trial.
Drug resistance
HIV
Viral load champion
Viral load monitoring
Virological failure
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
20 Dec 2021
20 Dec 2021
Historique:
received:
15
11
2021
accepted:
06
12
2021
entrez:
21
12
2021
pubmed:
22
12
2021
medline:
24
12
2021
Statut:
epublish
Résumé
There is poor viral load monitoring (VLM) and inadequate management of virological failure in HIV-positive individuals on antiretroviral therapy in rural KwaZulu-Natal, South Africa. This could be contributing to increasing HIV drug resistance in the setting. This study aims to investigate the clinical and process impediments in VLM within the health system and to evaluate a quality improvement package (QIP) to address the identified gaps. The QIP comprises (i) a designated viral load champion responsible for administrative management and triaging of viral load results (ii) technological enhancement of the routine clinic-based Three Interlinked Electronic Register (TIER.Net) to facilitate daily automatic import of viral load results from the National Health Service Laboratory to TIER.Net (iii) development of a dashboard system to support VLM. The study will evaluate the effectiveness of the QIP compared to current care for improving VLM and virological suppression using an effectiveness implementation hybrid type 3 design. This will use a cluster-randomised design with the primary healthcare clinics as the unit of randomisation with ten clinics randomised in a 1:1 ratio to either the intervention or control arm. We will enrol 150 HIV-positive individuals who had been on ART for ≥ 12 months from each of the ten clinics (750 in 5 intervention clinics vs. 750 in 5 control clinics) and follow them up for a period of 12 months. The primary outcome is the proportion of all patients who have a viral load (VL) measurement and are virally suppressed (composite outcome) after 12 months of follow up. Secondary outcomes during follow up include proportion of all patients with at least one documented VL in TIER.Net, proportion with VL ≥ 50 copies/mL, proportion with VL ≥ 1000 copies/mL (virological failure) and subsequent switch to second-line ART. We aim to provide evidence that a staff-centred quality improvement package, designated viral load monitoring champion, and augmentation of TIER.Net with a dashboard system will improve viral load monitoring and lead to improved virological suppression. This trial is registered on ClinicalTrials.gov on 8 Oct 2021. Identifier: NCT05071573; https://clinicaltrials.gov/ct2/show/NCT05071573?term=NCT05071573&draw=2&rank=1.
Sections du résumé
BACKGROUND
BACKGROUND
There is poor viral load monitoring (VLM) and inadequate management of virological failure in HIV-positive individuals on antiretroviral therapy in rural KwaZulu-Natal, South Africa. This could be contributing to increasing HIV drug resistance in the setting. This study aims to investigate the clinical and process impediments in VLM within the health system and to evaluate a quality improvement package (QIP) to address the identified gaps. The QIP comprises (i) a designated viral load champion responsible for administrative management and triaging of viral load results (ii) technological enhancement of the routine clinic-based Three Interlinked Electronic Register (TIER.Net) to facilitate daily automatic import of viral load results from the National Health Service Laboratory to TIER.Net (iii) development of a dashboard system to support VLM.
METHODS/DESIGN
METHODS
The study will evaluate the effectiveness of the QIP compared to current care for improving VLM and virological suppression using an effectiveness implementation hybrid type 3 design. This will use a cluster-randomised design with the primary healthcare clinics as the unit of randomisation with ten clinics randomised in a 1:1 ratio to either the intervention or control arm. We will enrol 150 HIV-positive individuals who had been on ART for ≥ 12 months from each of the ten clinics (750 in 5 intervention clinics vs. 750 in 5 control clinics) and follow them up for a period of 12 months. The primary outcome is the proportion of all patients who have a viral load (VL) measurement and are virally suppressed (composite outcome) after 12 months of follow up. Secondary outcomes during follow up include proportion of all patients with at least one documented VL in TIER.Net, proportion with VL ≥ 50 copies/mL, proportion with VL ≥ 1000 copies/mL (virological failure) and subsequent switch to second-line ART.
DISCUSSION
CONCLUSIONS
We aim to provide evidence that a staff-centred quality improvement package, designated viral load monitoring champion, and augmentation of TIER.Net with a dashboard system will improve viral load monitoring and lead to improved virological suppression.
TRIAL REGISTRATION
BACKGROUND
This trial is registered on ClinicalTrials.gov on 8 Oct 2021. Identifier: NCT05071573; https://clinicaltrials.gov/ct2/show/NCT05071573?term=NCT05071573&draw=2&rank=1.
Identifiants
pubmed: 34930182
doi: 10.1186/s12879-021-06952-5
pii: 10.1186/s12879-021-06952-5
pmc: PMC8686584
doi:
Banques de données
ClinicalTrials.gov
['NCT05071573']
Types de publication
Clinical Trial Protocol
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1266Subventions
Organisme : Royal Academy of Engineering
ID : FF\1920\1\23
Informations de copyright
© 2021. The Author(s).
Références
Public Health Action. 2018 Dec 21;8(4):225-231
pubmed: 30775284
PLoS One. 2007 Jan 17;2(1):e152
pubmed: 17225857
J Int AIDS Soc. 2014 Apr 28;17:18908
pubmed: 24780511
Sci Transl Med. 2017 Dec 13;9(420):
pubmed: 29237762
BMJ. 2012 Sep 04;345:e5661
pubmed: 22951546
HIV Med. 2020 Aug;21(7):457-462
pubmed: 32495515
Int J Epidemiol. 2021 Mar 3;50(1):33-34
pubmed: 33437994
AIDS Res Hum Retroviruses. 2016 Aug;32(8):763-9
pubmed: 27002368
AIDS. 2005 Jan 3;19(1):1-14
pubmed: 15627028
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Clin Infect Dis. 2019 Jul 2;69(2):207-214
pubmed: 30321314
Antivir Ther. 2008;13 Suppl 2:25-36
pubmed: 18575189
Nat Commun. 2020 Dec 1;11(1):5922
pubmed: 33262331
EClinicalMedicine. 2019 Mar 18;9:26-34
pubmed: 31143879
AIDS. 2014 Mar;28 Suppl 2:S161-9
pubmed: 24849476
Lancet Infect Dis. 2016 May;16(5):565-575
pubmed: 26831472